Healthcare Biz Rewind: Glaxo’s WITHDRAWAL, Quest’s Lucrative DEAL

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

GlaxoSmithKline (NYSE:GSK) shares move down as the firm withdraws a supplemental New Drug Application to the FDA for use of its Tykerb drug in unison with Genentech’s Herceptin for the treatment of a certain type of breast cancer in patients who have already received Herceptin. A spokesperson commented that, “Our discussions with FDA highlighted questions that could not be addressed with the data currently available.”

Investing Insights: J&J’s Second Quarter Earnings Sneak Peek.

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares gain almost 25 percent Thursday, while CEO Steven King was due to make a presentation at the JMP Securities Healthcare Conference in New York. The firm announced positive results from a Phase IIb trial of its bavituximab lung cancer treatment.

Quest Diagnostics (NYSE:DGX) shares move substantially up, to the revelation a 1996 deal with Merck (NYSE:MRK) over osteoporosis drug odanacatib, might pay off some $75 million.

Don’t Miss: These 4 Blue-Chips are NOT FOLDING after Jobless Report.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business